{
  "id": "af1eb10147904809",
  "title": "STAT+: Pharmalittle: We\u2019re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more",
  "description": "The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns",
  "content": "The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns",
  "source": "STAT",
  "source_url": "https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss",
  "published_at": "2026-01-15T14:12:57+00:00",
  "fetched_at": "2026-01-16T00:24:08.160649+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug",
    "trust",
    "ai",
    "fda"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Pharmalittle: We\u2019re reading about antitrust claims by a compounder, FDA and EMA AI rules, and more",
    "description": "The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns",
    "url": "https://www.statnews.com/pharmalot/2026/01/15/fda-antitrust-lilly-novo-compounders-insulin-ai-novartis/?utm_campaign=rss",
    "published": "2026-01-15T14:12:57+00:00",
    "source": "STAT"
  }
}